Inhibitor Therapeutics Inc. (INTI)
OTHER OTC:INTI
US Market
Holding INTI?
Track your performance easily

Inhibitor Therapeutics (INTI) Income Statement

26 Followers

Inhibitor Therapeutics Income Statement

Last quarter (Q ), Inhibitor Therapeutics's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Inhibitor Therapeutics's net income was $-501.69K. See Inhibitor Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
----$ 0.00$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 1.31M$ 3.40M$ 657.93K$ -325.39K$ 1.06M$ 2.75M
Operating Income
$ -2.86M$ -3.40M$ -657.93K$ -325.39K$ -1.06M$ -2.75M
Net Non Operating Interest Income Expense
$ 356.27K$ 378.84K$ -23.23K-$ 1.07K$ 14.54K
Other Income Expense
---$ -41.60K--
Pretax Income
$ -956.05K$ -3.03M$ 12.16M$ -298.63K$ -1.06M$ -2.73M
Tax Provision
-$ -131.49K$ 55.11K---
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -2.51M$ -3.03M$ 11.92M$ -498.63K$ -1.26M$ -2.93M
Basic EPS
-$ -0.02$ 0.03-$ >-0.01$ -0.01
Diluted EPS
-$ -0.02$ 0.03-$ >-0.01$ -0.01
Basic Average Shares
$ 688.38M$ 171.95M$ 366.18M$ 376.25M$ 371.93M$ 370.43M
Diluted Average Shares
$ 688.38M$ 171.95M$ 367.78M-$ 373.64M$ 370.43M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 1.31M$ 3.40M$ 657.93K$ -325.39K$ 1.06M$ 2.75M
Net Income From Continuing And Discontinued Operation
$ -2.51M$ -3.03M$ 12.11M$ -298.63K$ -1.06M$ -2.73M
Normalized Income
$ -1.54M-$ -3.01M-$ -1.06M$ -2.73M
Interest Expense
------
EBIT
$ -956.05K$ -3.16M$ 12.18M$ -283.80K$ -1.06M$ -2.75M
EBITDA
$ -956.05K$ -3.16M$ 12.18M$ -283.80K$ -1.06M$ -2.75M
Currency in USD

Inhibitor Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis